Experiment Overview
| Repository ID: | FR-FCM-Z24A | Experiment name: | Standardization of flow cytometric immunophenotyping for hematological malignancies: the FranceFlow group experience | MIFlowCyt score: | 24.75% |
| Primary researcher: | Ludovic LHERMITTE | PI/manager: | Ludovic LHERMITTE | Uploaded by: | Ludovic LHERMITTE |
| Experiment dates: | 2010-01-01 - 2017-12-30 | Dataset uploaded: | Jun 2019 | Last updated: | Apr 2024 |
| Keywords: | [Quality control] [interlaboratory comparisons] | Manuscripts: | |||
| Organizations: |
FranceFlow group, Paris, (France)
|
||||
| Purpose: | Flow cytometry is broadly used for the identification, characterization and monitoring of haematological malignancies. However, the use of clinical flow cytometry is restricted by its lack of reproducibility across multiple centres. Since 2006 the EuroFlow consortium has been developing a standardized procedure detailing the whole process from instrument settings to data analysis. The FranceFlow group was created in 2010 with the intention to educate participating centres in France about the standardised instrument setting protocol (SOP) developed by the EuroFlow consortium and to organise several rounds of quality controls (QCs) in order to evaluate the feasibility of its application and its results. Here, we report the 5 year experience of the FranceFlow group and the results of the seven QCs of 23 instruments, involving up to 19 centres, in France and in Belgium. | ||||
| Conclusion: | The FranceFlow group demonstrates that both the distribution and applicability of the SOP have been successful. Inter-center reproducibility was evaluated using both normal and pathological blood samples. Coefficients of variation (CVs) across the centers were <7% for the percentages of cell subsets and <30% for the MFIs of the markers tested. Intra-center reproducibility provided similar results with CVs of <3% for the percentages of the majority of cell subsets, and CVs of <20% for the MFI values for the majority of markers. Altogether, the FranceFlow group show that the 19 participating labs might be considered as one unique laboratory with 23 identical flow cytometers able to reproduce identical results. Therefore, SOP significantly improves reproducibility of clinical flow in hematology and opens new avenues by providing a robust companion diagnostic tool for clinical trials in hematology. | ||||
| Comments: | None | ||||
| Funding: | Not disclosed | ||||
| Quality control: | None | ||||
